BDTX Black Diamond Therapeutics Inc

Price (delayed)

$2.49

Market cap

$90.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.33

Enterprise value

$62.51M

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond ...

Highlights
The debt has surged by 99% year-on-year but it has declined by 2.4% since the previous quarter
The net income has contracted by 41% YoY but it has grown by 3.8% from the previous quarter
The company's equity fell by 39% YoY and by 12% QoQ

Key stats

What are the main financial stats of BDTX
Market
Shares outstanding
36.29M
Market cap
$90.36M
Enterprise value
$62.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$120.8M
EBITDA
-$120.49M
Free cash flow
-$106.97M
Per share
EPS
-$3.33
Free cash flow per share
-$2.95
Book value per share
$4.76
Revenue per share
$0
TBVPS
$6.05
Balance sheet
Total assets
$219.48M
Total liabilities
$46.92M
Debt
$27.45M
Equity
$172.56M
Working capital
$168.84M
Liquidity
Debt to equity
0.16
Current ratio
9.67
Quick ratio
9.29
Net debt/EBITDA
0.23
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47%
Return on equity
-57.6%
Return on invested capital
-58.5%
Return on capital employed
-60.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
2.05%
1 week
14.75%
1 month
49.1%
1 year
-79.74%
YTD
-53.28%
QTD
-10.11%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$121.84M
Net income
-$120.8M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 41% YoY but it has grown by 3.8% from the previous quarter
BDTX's operating income is down by 39% YoY but it is up by 4% QoQ

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has decreased by 40% YoY but it has increased by 4% QoQ
The P/B is 58% lower than the last 4 quarters average of 1.2
The company's equity fell by 39% YoY and by 12% QoQ

Efficiency

How efficient is Black Diamond Therapeutics business performance
Black Diamond Therapeutics's ROE has plunged by 113% YoY and by 8% from the previous quarter
BDTX's return on invested capital has dropped by 96% year-on-year and by 10% since the previous quarter
The ROA has shrunk by 84% YoY and by 5% QoQ

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
BDTX's total liabilities is up by 44% YoY but it is down by 9% QoQ
The quick ratio has contracted by 40% YoY but it has grown by 4% from the previous quarter
The debt is 84% smaller than the equity
The debt has surged by 99% year-on-year but it has declined by 2.4% since the previous quarter
The company's equity fell by 39% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.